Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
As bars and clubs look to reopening they are going to come under efficiency constraints. Margins are tight but they can be massively improved using the data analytics that Vianet provides. Knowledge is key, especially as post-lockdown trends will have to be reassessed. Vianet provides the information driven by consumer demand and choice - possession and use of that data will mean the difference between success and failure, surviving or closing. Data is all ways king and Vianet provides it in realtime.
Availability and cost of steel is going to be a key factor in keeping margins as existing contracts may have little leeway. I can't see a great improvement in the near future as the nature of the end products requires premium class raw material and margins/bottom line will suffer. Once we get a clearer picture into 2022 I'm more than happy to revisit as it's a good company.
Hope you're correct it's just the time lag before we know one way or another and I get the feeling it will tread water for 6 months. That means I can get a better return elsewhere and reinvest here in due course. Having said that, things could progress rapidly here with a few good contracts and I may miss the boat. Not an easy call, but one I've made on a gut feeling.
The outlook is sound but some way off from here given the constraints on steel supply primarily. If material availability and cost pressure hold back progress that is a brake to this year's earnings. Hopefully Vianet will benefit quickly and I'm happy to reinvest here in 6 months time as progress is more visible.
Immediate prospects are looking a lot clearer as lockdown end is clearly close. The company has performed creditably given exposure to the market but the future looks solid given that data analytics will help pubs and clubs maximise returns. This blip seems to be a decent entry point so my 'risk' punt capital is now here.
Decided to take the hit this morning and sold at a small loss as the outlook seemed sisyphean. Thankfully I was able to bunnyhop on to Vianet which itself saw a disproportionate drop this morning and pick up virtually the same number of shares. Been watching the latter as it's prospects should quickly pick up from here. Better of the two looking at market reaction but miffed that Pressure didn't get the traction due to a combination of factors. Heyho that's life.
Hopefully Pressure Tech are gaining the traction they envisaged and have banked the delayed MoD contract funds etc. I am expecting a really good update on the European hydrogen rollout with strongly visible indicators of cash flow.
I think £1.80 forecast is highly conservative given the outlook in both lockdown and business progress. Money has dropped into the coffers from large MoD extended contract during this period and uplift in o&g plus, as you say, pressurised H2 and N storage looks compelling for this specialist. As all pressurised equipment needs mandatory annual validation, the company should also be playing catch up and run soon if not already.
Cash flowing in....2 recent updates bode well.
CSC has a strong order book going into FY21, with high-margin projects, including the defence contract deferred from FY20, weighted to the first half of the year.
And from February
Pressure Technologies (AIM: PRES), the specialist engineering group, is pleased to announce that the outstanding principal of £3.1 million on the Promissory Note, payable under the Framework Agreement with Greenlane Renewables Inc., Creation Partners LLP and Brad Douville (the "Framework Agreement") announced on 3 July 2020, has been repaid in full, together with an interest payment of £0.3 million.
Repayment has been made earlier than the previously announced Promissory Note final maturity date of 30 June 2021 and concludes all arrangements made under the Framework Agreement
Looking good imo
Easing of lockdown also opens the doors to a huge volume of mandatory pressurised equipment testing that Pres is qualified to do and has to be done for customers on site and in situ. The backlog here must be substantial for Pressure Techs qualified inspectors. Plus oil and gas markets as well as hydrogen are opening up quickly.
The early receipt of the promissory note for £3.1m plus £0.4m interest plus receipt of the previously announced deferral of revenue on a defence contract from Q4 FY20 into Q1 FY21 should help interim progress as lockdown drops.
Looks like you're correct....confusing but have been watching for long time. My main reason was the payments due last year that will have been paid into current year telegraphed in finals. Onward and upward from here
I did the research but missed the low. I'm in. This is a selection of news items I gleaned over the weekend from Pres twitter, feed and Glossop/Buxton news.
Pressure tech
Next month we look forward to announcing the results of all our hard work and efforts with some very exciting news, and hopefully, some better weather!"
Pressure Tech in Hadfield has seen a 50 per cent increase in orders this year, which has presented its own challenges
The visit also provided the opportunity for the MP to see Pressure Tech’s success in the Green Hydrogen Fuel Cell market, with a recent order secured for 2,000 pressure regulators being exported to a key customer in the USA.
A recent contract win from the USA means the company needs to effectively double its production capacity, and Steve hopes to land two or three accounts with similar scope.
Managing director, Steve Yorke-Robinson explains: "Norway is absolutely a market of interest to us. Several of the world’s leading OEMs for Hydraulic Power Units (HPUs), Intervention Workover Control Systems (IWOCs) and Chemical Injection Systems are located in Norway, and these applications are key targets for our hydraulic pressure regulators in particular. In addition, Norway is a leader in subsea technology, so we expect the demand for our subsea pressure regulators to increase over the coming years and decades."
Pressure Tech's financial year started in November, so the end of April marked the half way point.
We are pleased to announce that we have made a fantastic start, with a 65% increase in sales order intake compared to last year!
It also marks a record order entry for the first 6 months in any of our previous 20+ years!
Do with it as you will.
........and that Naked Trader gave reasoned arguments for investment on two purchases at 5.35 and 5.95p with a current target of 10p. He currently holds 250k so interesting diversity of opinion. My gut feeling is for an 'all will be revealed' finals bonanza on the 14th as deals are signed and value surfaces.
Stockopedia is showing results due 10th June. Don't know how info obtained but at least it's showing next week. Think a lot will be resolved and share price should bounce nicely from here as it's 20% below last fundraise, is debt free and has a lot of positives in the mix. I've reinvested a punt amount at this level expecting a very decent short term return on 5.33p paid. Interestingly undervalued imo given t/o versus MCap.
The inflection point that will rerate GSK is close. The shingles vaccine has huge earnings potential for turnover and profit as does the transformational investment in Curevac but investors seem to be focussing on Elliott. Not that relevant in the bigger picture that is unfolding. Clarity on the GSK split this month should accelerate the rerate.